Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial
2022 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial
Andreas, S. ; Testa, M.; Boyer, L.; Brusselle, G.; Janssens, W.; Kerwin, E. & Papi, A. et al. (2022)
The Lancet Respiratory Medicine, 10(5) pp. 435-446. DOI: https://doi.org/10.1016/S2213-2600(21)00502-6
Documents & Media
Details
- Authors
- Andreas, Stefan ; Testa, Marco; Boyer, Laurent; Brusselle, Guy; Janssens, Wim; Kerwin, Edward; Papi, Alberto; Pek, Bonavuth; Puente-Maestu, Luis; Saralaya, Dinesh; Arora, Ashwani K
- Issue Date
- 2022
- Journal
- The Lancet Respiratory Medicine
- Organization
- Klinik für Kardiologie und Pneumologie
- ISSN
- 2213-2600
- Language
- English
